Grail Hit with Shareholder Class Action Suit Over NHS-Galleri Trial Remarks

The suit alleges that Grail executives concealed the “true state” of the company’s NHS-Galleri trial, which did not meet its primary endpoint.

A Grail investor has launched a class action suit against the liquid biopsy company, alleging that Grail officials misled investors about the chances of success in its key NHS-Galleri trial.

In a complaint filed June 5 in the US District Court for the Northern District of California, plaintiff William Robbins alleged that Grail officials, including current CEO Joshua Offman, former CEO Bob Ragusa, and Chief Scientific Officer Harpal Kumar provided “overwhelmingly positive statements [about the NHS-Galleri trial] to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Grail’s NHS-Galleri trial following the reveal of the top-line results covering the first screening round.”

In February, Grail disclosed that the trial had not met its primary endpoint of showing that Galleri multi-cancer early detection testing would lead to a reduction in Stage 3 and 4 cancers in the study population. Grail presented full results from the study at the recent annual meeting of the American Society of Clinical Oncology in late May.

The result was a blow to Grail’s plans to sell the test to everyone over the age of 50, rather than target people based on cancer risk factors.

As of June 12, shares of Grail are down approximately 40 percent compared to where they were trading prior to the disclosure in February.

The class includes anyone who purchased Grail common stock between May 13, 2025 and February 19, 2026.

The complaint asked for damages and a trial by jury.